JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Relationship between pancreatic cancer and Maresin 1
Abstract
Aims: Pancreatic cancer is the 4th most common cause of death from cancer. In addition, pancreatic cancer is the most common primary malignant tumor of the pancreas. There are many risk factors for pancreatic cancer, including age, certain genetic syndromes, smoking, diabetes, alcohol abuse and obesity. In our study, we aimed to evaluate the role of Maresin 1 (MaR1), which is responsible for the resolution of inflammation, in the pathogenesis of pancreatic cancer and its differential power between chronic pancreatitis and pancreatic cancer.
Methods: The study included 47 patients diagnosed with pancreatic cancer, 32 patients diagnosed with chronic pancreatitis, and 30 volunteers without any additional disease who applied to the internal medicine polyclinic for routine control, who applied to our clinic since October 2021 and accepted to participate in the study. MaR1 levels were measured using the ELISA technique from blood samples obtained from these volunteers.
Results: In our study, MaR1 level was 374.42 (97.27-74.129) pg/ml in the pancreatic cancer group, 491.39 (252.66-949.28) pg/ml in the chronic pancreatitis group and 558.53 (286.94) in the healthy control group. -886,68) pg/ml was measured. There was a significant difference between the pancreatic cancer patients group and the chronic pancreatitis patients and healthy control group. In the pancreatic cancer patient group, MaR1 level was found to be lower than the chronic pancreatitis group (p=0.01). In our ROC analysis, the discriminative performance of MaR1 (AUC=0.651; [95%CI: 0.535-0.754]; p=0.0169 values) was found to be high in predicting patients with pancreatic cancer according to the patient group with chronic pancreatitis. For MaR1 ?315.52 cut-off point sensitivity was 36.17% and selectivity was 90.62%.
Conclusion: Proinflammatory cytokines, which have a role in the pathogenesis of pancreatic cancer, increase as a result of the decrease in lipid mediators involved in resolution pathways. Reduction of MaR1 may trigger chronic inflammation and pancreatic carcinogenesis. MaR1 may make an important diagnostic contribution in clinical practice in predicting the progression of patients with chronic pancreatitis to pancreatic cancer.

Keywords : Pancreatic cancer, chronic pancreatitis, inflammation, resolution, Maresin 1

Download Article


1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018;68(6):394-424. doi:10.3322/caac.21492
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev.2006;20(10):1218-1249. doi:10.1101/gad.1415606
3. Lin Y, Yagyu K, Egawa N, et al. An overview of genetic polymorphismsand pancreatic cancer risk in molecular epidemiologic studies. JEpidemiol. 2011;21(1):2-12. doi:10.2188/jea.je20100090
4. Miller RC, Petereit DG, Sloan JA, et al. N08C9 (Alliance): a phase 3randomized study of sulfasalazine versus placebo in the prevention ofacute diarrhea in patients receiving pelvic radiation therapy. Int J RadiatOncol Biol Phys. 2016;95(4):1168-1174. doi:10.1016/j.ijrobp.2016.01.063
5. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, andnational burden of pancreatic cancer and its attributable risk factors in195 countries and territories, 1990-2017: a systematic analysis for theGlobal Burden of Disease Study 2017. Lancet Gastroenterol Hepatol.2019;4(12):934-947. doi:10.1016/S2468-1253(19)30347-4
6. Zhang YH, Zhang CW, Hu ZM, Hong DF. Pancreatic cancer: open orminimally invasive surgery?. World J Gastroenterol. 2016;22(32):7301-7310. doi:10.3748/wjg.v22.i32.7301
7. Pan G, Zhang P, Yang J, Wu Y. The regulatory effect of specializedpro-resolving mediators on immune cells. Biomed Pharmacother.2022;156:113980. doi:10.1016/j.biopha.2022.113980
8. Saito-Sasaki N, Sawada Y, Nakamura M. Maresin-1 and InflammatoryDisease. Int J Mol Sci. 2022;23(3):1367. doi:10.3390/ijms23031367
9. Abdulnour RE, Dalli J, Colby JK, et al. Maresin 1 biosynthesis duringplatelet-neutrophil interactions is organ-protective. Proc Natl Acad SciU S A. 2014;111(46):16526-16531. doi:10.1073/pnas.1407123111
10. Gandhi S, de la Fuente J, Murad MH, Majumder S. Chronic pancreatitisis a risk factor for pancreatic cancer, and incidence increases withduration of disease: a systematic review and meta-analysis. Clin TranslGastroenterol. 2022;13(3):e00463. doi:10.14309/ctg.0000000000000463
11. Glaubitz J, Wilden A, Golchert J, et al. In mouse chronic pancreatitisCD25+FOXP3+ regulatory T cells control pancreatic fibrosisby suppression of the type 2 immune response. Nat Commun.2022;13(1):4502. doi:10.1038/s41467-022-32195-2
12. Le Cosquer G, Maulat C, Bournet B, Cordelier P, Buscail E, Buscail L.Pancreatic cancer in chronic pancreatitis: pathogenesis and diagnosticapproach. Cancers (Basel). 2023;15(3):761. doi:10.3390/cancers15030761
13. Lu Y, Lu G, Gao L, et al. The proresolving lipid mediator maresin1 alleviatesexperimental pancreatitis via switching macrophage polarization.Mediators Inflamm. 2021;2021:6680456. doi:10.1155/2021/6680456
14. Jung TW, Kim HC, Abd El-Aty AM, Jeong JH. Maresin 1 attenuatesNAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway. J Biol Chem. 2018;293(11):3981-3988. doi:10.1074/jbc.RA117.000885
15. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels candistinguish between benign and malignant pancreaticobiliary disease.Hepatobiliary Pancreat Dis Int. 2009;8(6):620-626.
16. Gu J, Luo L, Wang Q, et al. Maresin 1 attenuates mitochondrialdysfunction through the ALX/cAMP/ROS pathway in the cecalligation and puncture mouse model and sepsis patients. Lab Invest.2018;98(6):715-733. doi:10.1038/s41374-018-0031-x
17. Grote VA, Rohrmann S, Nieters A, et al. Diabetes mellitus, glycatedhaemoglobin and C-peptide levels in relation to pancreatic cancer risk:a study within the European Prospective Investigation into Cancerand Nutrition (EPIC) cohort. Diabetologia. 2011;54(12):3037-3046.doi:10.1007/s00125-011-2316-0
18. Huxley R, Ansary-Moghaddam A, Berrington de González A, BarziF, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076-2083. doi:10.1038/sj.bjc.6602619
19. Qian J, Tao D, Shan X, Xiao X, Chen C. Role of angiogenesis in beta-cell epithelial-mesenchymal transition in chronic pancreatitis-induceddiabetes. Lab Invest. 2022;102(3):290-297. doi:10.1038/s41374-021-00684-5
20. Popovic K, Smolovic B, Martinovic M, Vuckovic L. The relatıonshipbetween diabetes mellitus and pancreatic cancer-diabetes mellitus as ared flag for pancreatic cancer. Cancer Epidemiol Biomark Prevent. 2023.doi:10.1158/1055-9965.EPI-22-0951
Article available in :
Volume 1, Issue 2, 2023
Page : 18-23
https://doi.org/10.51271/JCHOR-0006
Article Information
Received : 06 Mar 2023
Accepted : 27 Nis 2023
Published : 29 May 2023
Corresponding Author :

Özlem Gül: Division of Gastroenterology, Department of InternalMedicine, Faculty of Medicine, Kırıkkale University, Kırıkkale, TURKEY

[email protected]
Citation : Varol H, Gül Ö, Ergül B, Kısa Ü, Tekin E, Oğuz D. Relationship between pancreatic cancer and Maresin 1. J Curr Hematol Oncol Res. 2023;1(2):18-23.

Read: 266
Cited: 0
Download : 214
_Footer